CSPC indacaterol mometasone inhalation powder has been approved for clinical trials in China.
March 10, 2026
Source: drugdu
31
On March 5, CSPC Pharmaceutical Group (1093.HK) announced that...The indacaterol mometasone inhalation powder developed by our Group (hereinafter referred to as "the Product") has been approved by the National Medical Products Administration and can be used for clinical trials in China.
This product is used for maintenance treatment of asthma in adults and adolescents aged 12 years and older. Indacaterol is a long-acting β2-adrenergic agonist (LABA) with smooth muscle relaxant and bronchodilator effects. Mometasone furoate is an inhaled corticosteroid (ICS) with local anti-inflammatory effects. Indacaterol-Mometasone Inhalation Powder is the first once-daily inhaled ICS-LABA dual-combination inhaled formulation included in the National Medical Insurance Catalog (2022 Edition), providing asthma patients with a more efficient and convenient treatment option.
The approval of the clinical trial for this product is another important achievement of the Group's high-end innovative inhalation technology platform, laying a solid foundation for the development of subsequent inhalation formulations in the pipeline.
https://bydrug.pharmcube.com/news/detail/05366d40770ea305aa0b4013b8af4f4e
Copyright©2026 Ddu. All rights reserved.
Read more on
- Novogene® has been approved, making its global debut in China! March 10, 2026
- Hengrui Medicine subsidiary’s HRS9531 injection has been approved for clinical use in chronic kidney disease March 10, 2026
- Junshi Biosciences’ marketing application for toripalimab injection (subcutaneous injection) has been accepted March 10, 2026
- ATTC Platform Shines https March 10, 2026
- Are the problems with OX40 more serious than we thought? March 10, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
